Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GenDerm v. Stiefel Labs

This article was originally published in The Tan Sheet

Executive Summary

Patent infringement complaint filed Oct. 14 seeks to bar Stiefel Labs from infringing GenDerm's capsaicin composition patent for Zostrix and Zostrix HP OTC topical analgesic creams. Filed in U.S. District Court for the Southern District of Florida, the complaint claims that Stiefel has infringed the patent by making, using and/or selling topical creams containing the capsaicin compositions. The complaint also seeks treble damages, including lost or reduced profits and attorney's fees. Stiefel subsidiary Glades Pharmaceutical plans to introduce its topical capsaicin cream into national distribution this month. GenDerm also has a suit pending against Ferndale Labs for infringement of two of its capsaicin patents and for trade dress infringement. Zostrix and Zostrix HP have combined annual sales of approximately $20 mil
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel